HYBRiD-XL Platform Development

About DRG International

DRG International is a well-established, revenue-generating diagnostics company specializing in immunoassay development, manufacturing, and distribution. Its core offerings include ELISA kits for areas like autoimmune diseases, cancer, cardiac markers, and infectious diseases, alongside the DRG:HYBRiD-XL automated analyzer and distribution of CHROMagar media. Acquired by BioCheck, Inc. in 2021, the company leverages ISO 13485:2016 and MDSAP certifications to serve a broad international market through a direct and distributor network. Its strategy focuses on providing accessible, high-quality diagnostic tools to enable earlier treatment intervention.

Therapeutic Areas

Other Laboratory Automation Drugs